Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,436
  • Shares Outstanding, K 18,786
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,290 K
  • 60-Month Beta 2.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.42
Trade DMAC with:

Options Overview Details

View History
  • Implied Volatility 136.54%
  • Historical Volatility 62.24%
  • IV Percentile 60%
  • IV Rank 46.76%
  • IV High 268.74% on 01/27/21
  • IV Low 20.46% on 04/14/21
  • Put/Call Vol Ratio 0.10
  • Today's Volume 32
  • Volume Avg (30-Day) 255
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 30
  • Open Int (30-Day) 1,040

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +30.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.38 +1.48%
on 12/03/21
4.80 -28.54%
on 11/08/21
-0.94 (-21.51%)
since 11/03/21
3-Month
3.38 +1.48%
on 12/03/21
4.82 -28.84%
on 09/27/21
-0.67 (-16.34%)
since 09/03/21
52-Week
3.00 +14.33%
on 08/13/21
10.88 -68.47%
on 02/19/21
-1.67 (-32.75%)
since 12/03/20

Most Recent Stories

More News
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will...

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S....

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its third...

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that late-breaking...

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S....

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing...

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics Announces $30 Million Private Placement

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced it has entered...

DMAC : 3.43 (-3.38%)
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation...

DMAC : 3.43 (-3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada....

See More

Key Turning Points

3rd Resistance Point 3.81
2nd Resistance Point 3.72
1st Resistance Point 3.57
Last Price 3.43
1st Support Level 3.33
2nd Support Level 3.24
3rd Support Level 3.09

See More

52-Week High 10.88
Fibonacci 61.8% 7.87
Fibonacci 50% 6.94
Fibonacci 38.2% 6.01
Last Price 3.43
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar